A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: marks (231), results (1000)

MyelomaVCD(SC21)Bortezomib(SC)CyclophosphamideDexamethasone21dayVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-21) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (21 day) Regimen Multiple Myeloma – VCD (SC-21)-Bortezomib (SC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDSC21BortezomibSCCyclophosphamideDexamethasone21dayVer1.pdf

MyelomaVCD(IV28)Bortezomib(IV)CyclophosphamideDexamethasone28dayVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-28) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (28 day) Regimen Multiple Myeloma – VCD (IV-28)-Bortezomib (IV
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDIV28BortezomibIVCyclophosphamideDexamethasone28dayVer1.pdf

Myeloma VCD (SC35) bortezomib (SC) cyclophosphamide dexamethasone 35 day

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-35) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (SC-35)-Bortezomib (SC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-SC35-bortezomib-SC-cyclophosphamide-dexamethasone-35-day.pdf

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (IV-35)-Bortezomib (IV
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

Apalutamide v1

Description
Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate cancer as defined by recent imaging
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Lenalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA LENALIDOMIDE Regimen • Multiple Myeloma – Lenalidomide Indication • Lenalidomide is recommended, within its licensed indication, as an option for
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Lenalidomide.pdf

Cyclophosphamide-Docetaxel Ver 1.1

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL Regimen Breast Cancer – Cyclophosphamide-Docetaxel Indication Adjuvant therapy for early breast cancer when anthracyclines are
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/BreastCyclophosphamideDocetaxelVer11.pdf

Epirubicin Fluorouracil Oxaliplatin (EOF)

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER EPIRUBICIN, FLUOROURACIL and OXALIPLATIN (EOF) Regimen • Gastrointestinal Cancer (upper) – Epirubicin-Fluorouracil-Oxaliplatin (EOF) Indication • First line
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Epirubicin-Fluorouracil-Oxaliplatin-EOF.pdf

Cisplatin-Etoposide (intravenous and oral)

Description
Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CISPLATIN-ETOPOSIDE (Intravenous / Oral) Regimen SCLC – Cisplatin-Etoposide IV/PO Indication Limited stage SCLC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Cisplatin-Etoposideintravenousandoral.pdf

Cisplatin-Etoposide (intravenous)

Description
Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CISPLATIN-ETOPOSIDE (Intravenous) Regimen SCLC – Cisplatin-Etoposide IV Indication Limited stage SCLC Usually given
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Cisplatin-Etoposideintravenous.pdf
211 to 220 of 548
Previous … 20 21 22 23 24 … Next